Medtronic To Separate Diabetes Business

Medtronic, which offers health care technology, announced its intent to separate its diabetes business into a new standalone company that will sell products directly to consumers. This strategic decision is intended to create a simplified portfolio in high-margin growth markets. The new diabetes company will commercialize a complete, intensive insulin management ecosystem for people with diabetes.

The separation is expected to be completed within 18 months, through a series of capital markets transactions and a preferred path of an initial public offering and subsequent split-off. The independent diabetes company will have a shareholder base aligned with its business . . .